Hemostemix Inc. (CVE:HEM – Get Free Report) rose 31% on Thursday . The stock traded as high as C$0.23 and last traded at C$0.19. Approximately 480,687 shares were traded during trading, a decline of 9% from the average daily volume of 525,664 shares. The stock had previously closed at C$0.15.
Hemostemix Trading Down 7.9 %
The stock has a market cap of C$25.50 million, a P/E ratio of -5.10 and a beta of 0.20. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The company has a 50-day moving average price of C$0.20 and a two-hundred day moving average price of C$0.12.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- Election Stocks: How Elections Affect the Stock Market
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- DuPont’s Electronics Spinoff: The Start of Something Big
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
